Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1

1(33.3%)

N/A

1(33.3%)

Phase 3

1(33.3%)

3Total

Phase 1(1)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT05896826Recruiting

Magnetocardiography in the Accurate Identification of Myocardial Infarction

Role: collaborator

NCT06197724Recruiting

MCG for Identification of Myocardial Ischemia in Suspected NSTE-ACS Patients

Role: collaborator

NCT06649422Not Yet Recruiting

Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study

Role: collaborator

NCT06316011Recruiting

MCG for Risk Stratifications of Patients With Chest Pain

Role: collaborator

NCT05392712Not ApplicableRecruiting

Magnetocardiography in the Accurate Identification of Severe Coronary Lesions and Myocardial Necrosis

Role: collaborator

NCT06198777Unknown

Determination of MCG Reference Intervals in Healthy Individuals

Role: collaborator

NCT04958447Unknown

Nutritional Management in Respiratory Critically Ill Patients -an Observational Study in Mainland China

Role: collaborator

NCT03930940Phase 1Completed

Remote Ischemic Conditioning for Intracerebral Hemorrhage

Role: collaborator

NCT03510832Unknown

Evaluation of Antithrombotic STrategies in STEMI Patients in China

Role: collaborator

NCT02985372Phase 3Unknown

Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia

Role: collaborator

NCT01875484Completed

Circulating miR-126 as a Novel Biomarker for Post Myocardial Infarction Remodeling

Role: collaborator

All 11 trials loaded